[By ktsdesign/Adobe Stock]
On a recent visit to Nvidia’s headquarters in Santa Clara, I had the chance to speak with Kimberly Powell, the company’s vice president and general manager of healthcare. After asking about the pharma industry’s surging interest in AI, Powell remarked, “Every pharma knows who Nvidia is now.” Curious, I asked her, “How long has that been the case?” Without batting an eye, she replied: “Since December.” While some R&D professionals in pharma were aware of the company, awareness was not pervasive until recently. The December timing is not a coincidence. OpenAI’s ChatGPT rolled out on November 30, 2022. ChatGPT, which runs on Nvidia hardware, has prompted a reprioritization of AI in the industry. As Powell described it: “From the top down, every group is saying, go do at least two things using AI, and report back. They are really just starting to make it part of the DNA of the c…A deep dive into AWS’s strategy with generative AI and ML in life sciences
[Image Fabrizio/Adobe Stock]
The AI market is witnessing meteoric growth, with projections hinting at a potentially staggering increase over the next decade. Against this backdrop of rapid AI evolution, we recently spoke with Tehsin Syed, general manager of AWS Health. Syed shared that Amazon Web Services (AWS) is seeing growing interest from Big Pharma firms. “Nine of the top 10 pharma companies in the world have a large majority of the workloads running on AWS,” Syed said. The AWS cloud hosts more than 100,000 customers across industries.AWS aims to provide a broad and deep range of AI services and takes an end-to-end approach to AI that includes infrastructure, software, hardware and services.In an increasingly competitive AI landscape, AWS recently launched a $100 million initiative, the AWS Generative AI Innovation Center, to accelerate enterprise generative AI adoption. As Syed put it, “AWS has a pe…